1. Infection profile of immune-modulatory drugs used in autoimmune diseases: Analysis of summary of product characteristic data;Dey;RMD Open.,2022
2. Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: A systematic review and meta-analysis of 1429 patients;Müller;Vaccine.,2022
3. Consejo Interterritorial. Sistema Nacional de Salud. Recomendaciones de utilización de Evusheld para la prevención de COVID-19 [consultado el 10 de octubre de 2022].. Disponible en: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/Recomendaciones_uso_Evusheld.pdf
4. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters;Conte;Mult Scler Relat Disord.,2022
5. Birabaharan M, Hill E, Begur M, Kaelber DC, Martin TC, Mehta SR. Cardiovascular outcomes after tixagevimab and cilgavimab use for pre-exposure prophylaxis against COVID-19: a population-based propensity-matched cohort study. Clin Infect Dis. 2022;16:ciac894.